Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system
Authors
Keywords
-
Journal
European Journal of Preventive Cardiology
Volume -, Issue -, Pages 204748732091566
Publisher
SAGE Publications
Online
2020-04-21
DOI
10.1177/2047487320915663
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction
- (2019) Jesse F Veenis et al. European Journal of Preventive Cardiology
- Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
- (2019) Emanuel Raschi et al. Targeted Oncology
- Real-world prevalence of adverse events after initiating sacubitril/valsartan compared to angiotensin converting enzyme inhibitors or angiotensin receptor blockers in systolic heart failure
- (2019) Sarah Adie et al. JOURNAL OF CARDIAC FAILURE
- Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction
- (2019) Pieter Martens et al. Clinical Research in Cardiology
- Sacubitril/valsartan eligibility and outcomes in the ESC HFA EORP Heart Failure Long‐Term Registry: bridging between EMA/FDA label, the PARADIGM‐HF trial, ESC Guidelines, and real‐world
- (2019) Chris J. Kapelios et al. EUROPEAN JOURNAL OF HEART FAILURE
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
- (2019) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis
- (2019) Kanila Perera et al. European Journal of Preventive Cardiology
- Impact of Sacubitril/Valsartan on the Long-Term Incidence of Ventricular Arrhythmias in Chronic Heart Failure Patients
- (2019) Ibrahim El-Battrawy et al. Journal of Clinical Medicine
- Three case reports of involuntary muscular movements as adverse reactions to sacubitril/valsartan
- (2018) Theodora Bejan-Angoulvant et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Ventricular Arrhythmic Storm after Initiating Sacubitril/Valsartan
- (2018) Lourdes Vicent et al. CARDIOLOGY
- Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey
- (2018) Florence Moulis et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Do we still need ICDs if we have ARNi?
- (2018) Joachim R. Ehrlich HEART RHYTHM
- Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices
- (2018) Carlos de Diego et al. HEART RHYTHM
- Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database
- (2018) Amichai Perlman et al. JOURNAL OF CARDIAC FAILURE
- Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems
- (2018) E. Raschi et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Efficacy of renin–angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease
- (2018) Tetsuro Tsujimoto et al. European Journal of Preventive Cardiology
- A step forward in resolving an old issue: treatment of heart failure with preserved ejection fraction and renal dysfunction?
- (2018) Petar M Seferović et al. European Journal of Preventive Cardiology
- Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients
- (2018) Valerio Zacà Journal of Cardiovascular Medicine
- Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction
- (2018) Sercan Okutucu et al. ACTA CARDIOLOGICA
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
- (2018) Joe-Elie Salem et al. LANCET ONCOLOGY
- Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides
- (2017) Emilia D'Elia et al. EUROPEAN JOURNAL OF HEART FAILURE
- Heart failure in patients with kidney disease
- (2017) Courtney Tuegel et al. HEART
- Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction
- (2016) Jane A. Cannon et al. EUROPEAN JOURNAL OF HEART FAILURE
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2016) Piotr Ponikowski et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System
- (2016) E. Raschi et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
- (2015) Akshay S. Desai et al. EUROPEAN HEART JOURNAL
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
- (2014) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Choosing Thresholds for Statistical Signal Detection with the Proportional Reporting Ratio
- (2013) Jim Slattery et al. DRUG SAFETY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started